Centrient Pharmaceuticals, a Dutch specialist in antibiotics and active pharmaceutical ingredients (APIs), has announced the appointment of Pierre-Yves Dalla-Libera as the new Site Director for its Delft facility, effective September 1, 2025.

He will succeed Luigi De Martin, who is leaving the company to explore new opportunities.

Centrient’s Delft site, the only facility in the Netherlands producing antibiotic ingredients, plays a crucial role in ensuring a stable, resilient supply of life-saving medicines across Europe and beyond.

Pierre-Yves, who has been with Centrient for the past three years, has held several senior positions, including Head of External Supply Operations for Active Pharmaceutical Ingredients (ESO API), interim Site Head at Santa Perpetua, and Global Strategy Director for TechOps.

Before joining Centrient, he held roles at Sanofi Pasteur and Centrale Lille, building extensive experience in strategic planning, project management, and international operations.

A French national, Pierre-Yves holds a degree in IT, business, and engineering from Centrale Lille.

Vesna Kapelj, Chief Technical Operations Officer at Centrient, said: “Pierre-Yves’s appointment demonstrates our commitment to empowering our people to take on critical leadership roles that drive our strategy forward.”

“I am confident that under his leadership, our Delft site will continue to deliver high-quality antibiotics, support Europe’s health resilience, and contribute to a healthier future for all.”

Headquartered in Rotterdam, Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. It produces and sells intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs).

The firm, owned by Bain Capital Private Equity, has production facilities and sales offices in China, India, the Netherlands, Spain, the United States, and Mexico.